Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPRT1 | P00492 | 11/20 | 0.66 |
| ▸ | PNP | P00491 | 8/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | TK1 | P04183 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6834479 | 1.00 | HPRT1 (0.66) | HPRT1PNPPOLBTK1 | |
| SCHEMBL11374638 | 0.84 | HPRT1 (0.67) | HPRT1PNPTK1 | |
| SCHEMBL1732931 | 0.84 | HPRT1 (0.67) | HPRT1PNPTK1 | |
| SCHEMBL1732928 | 0.84 | HPRT1 (0.67) | HPRT1PNPTK1 | |
| Gs-438 SCHEMBL64567 | 0.82 | POLB (0.80) | HPRT1PNPPOLB | |
| SCHEMBL8896276 | 0.81 | HPRT1 (0.81) | HPRT1PNPPOLB | |
| SCHEMBL8895437 | 0.81 | HPRT1 (0.74) | HPRT1PNP | |
| SCHEMBL8896272 | 0.81 | HPRT1 (0.72) | HPRT1PNP | |
| SCHEMBL8898386 | 0.81 | HPRT1 (0.80) | HPRT1PNPPOLB | |
| SCHEMBL8905164 | 0.81 | HPRT1 (0.72) | HPRT1PNPPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040068111-A1 | Unsaturated phosphonate derivatives of purines and pyrimidines | AVENTIS PHARMACEUTICALS INC. | 2004-04-08 | — | — | US | claimed |
| US-20030004345-A1 | Unsaturated phosphonate derivatives of purines and pyrimidines | CASARA PATRICK (FR) | 2003-01-02 | — | — | US | claimed |
| EP-0701562-B1 | UNSATURATED PHOSPHONATES DERIVATIVES OF PURINES AND PYRIMIDINES | MERRELL PHARMA INC (US) | 1997-06-18 | — | — | EP | claimed |
| EP-0701562-A1 | UNSATURATED PHOSPHONATES DERIVATIVES OF PURINES AND PYRIMIDINES | MERRELL DOW PHARMA (US) | 1996-03-20 | — | — | EP | claimed |
| WO-1994022882-A1 | UNSATURATED PHOSPHONATES DERIVATIVES OF PURINES AND PYRIMIDINES | MERRELL DOW PHARMACEUTICALS INC. (US) | 1994-10-13 | — | — | WO | claimed |
| EP-0618214-A1 | Unsaturated phosphonate derivatives of purines and pyrimidines | MERRELL DOW PHARMACEUTICALS INC. (US) | 1994-10-05 | — | — | EP | claimed |
| US-20040068111-A1 | Unsaturated phosphonate derivatives of purines and pyrimidines | AVENTIS PHARMACEUTICALS INC. | 2004-04-08 | — | — | US | disclosed |
| US-20030004345-A1 | Unsaturated phosphonate derivatives of purines and pyrimidines | CASARA PATRICK (FR) | 2003-01-02 | — | — | US | disclosed |
| US-5922696-A | VIRICIDES AGAINST DNA VIRUSES, RETROVIRUSES AND VIRUSES INVOLVED IN TUMOR FORMATION, CYTOMEGALOVIRUS, VARICELLA-ZOSTER VIRUS, EPSTEIN-BARR VIRUS, HUMAN IMMUNODEFICIENCY VIRUSES | MERRELL PHARMACEUTICALS INC. (US) | 1999-07-13 | — | — | US | disclosed |
| US-5817647-A | VIRICIDES; ANTITUMOR AGENTS | MERRELL PHARMACEUTICALS INC. (US) | 1998-10-06 | — | — | US | disclosed |
| EP-0701562-B1 | UNSATURATED PHOSPHONATES DERIVATIVES OF PURINES AND PYRIMIDINES | MERRELL PHARMA INC (US) | 1997-06-18 | — | — | EP | disclosed |
| EP-0701562-A1 | UNSATURATED PHOSPHONATES DERIVATIVES OF PURINES AND PYRIMIDINES | MERRELL DOW PHARMA (US) | 1996-03-20 | — | — | EP | disclosed |
| WO-1994022882-A1 | UNSATURATED PHOSPHONATES DERIVATIVES OF PURINES AND PYRIMIDINES | MERRELL DOW PHARMACEUTICALS INC. (US) | 1994-10-13 | — | — | WO | disclosed |
| EP-0618214-A1 | Unsaturated phosphonate derivatives of purines and pyrimidines | MERRELL DOW PHARMACEUTICALS INC. (US) | 1994-10-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040068111-A1 | Unsaturated phosphonate derivatives of purines and pyrimidines | TYMP, NUDT1, PNP | HPRT1 8/4885PNP 3/4885POLB 100/4885 |
| US-20030004345-A1 | Unsaturated phosphonate derivatives of purines and pyrimidines | TYMP, NUDT1, PNP | HPRT1 8/4885PNP 3/4885POLB 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.